Navigation Menu:

• About Us
• Meet the Team
• Schedule a Consultation

Please remember to cite the Shared Resources!

Research reported in this publication was supported by The Ohio State University Comprehensive Cancer Center and the National Institutes of Health under grant number P30 CA016058.

We thank the XX Shared Resource at The Ohio State University Comprehensive Cancer Center, Columbus, OH for (XX)

About Us (back to top)

• The Veterinary Biospecimen Respository
• Blue Buffalo Clinical Trials Office

The Veterinary Biospecimen Repository

The Veterinary Biospecimen Repository collects samples of tumors and normal tissue and stores these tissues under controlled conditions for future use by multiple investigators. Following established collection guidelines for sample collection and processing, tissues are collected and archived only after receiving consent from the owners. This repository has been providing samples to researchers at The Ohio State University , Nationwide Children's Hospital, other universities and research institutes resulting in the identification of new targets for therapy in osteosarcoma, melanoma, lymphoma, and pulmonary carcinoma common to both humans and canines. As a result, these efforts have generated several new research opportunities that will benefit human and animal patients. The Veterinary Biospecimen Repository represents a remarkable resource that continues to assist investigators as they strive to develop new prevention and treatment strategies for both animals and people with a variety of illnesses.

Veterinary Medical Center
601 Vernon L. Tharp St.
Columbus, OH 43210

Phone: 614-247-8706
Fax: 614-247-8428
CVM-ClinicalTrials@osu.edu

Available services

• Frozen, FFPE, OCT tumor tissue
• Pair normal and tumor samples
• Normal biofluids for matched controls
• Complete sets of tumor, blood and urine from the same animal
• Primary tumor and associated metastatic lesions
• Custom prospective collections on request

Blue Buffalo Veterinary Clinical Trials Office (back to top)

The Blue Buffalo Veterinary Clinical Trials Office (BBVCTO) provides support to faculty members and industry sponsors conducting clinical trials and ensures regulatory compliance. BBVCTO provides assistance in the design, execution, and evaluation of veterinary clinical trials using client-owned animals, with the overarching goal of advancing the diagnosis and treatment of disease in veterinary patients while enhancing the health of humans.​ Client-owned animals develop spontaneous and genetic cancers, many of which are remarkably similar to human cancers. Clinical research in veterinary patients can serve as a mechanism to develop and explore new therapeutic targets, document safety and toxicity in a population with clinical comorbidities and confirm treatment effects in a natural population of tumor-bearing veterinary patients. Pre-clinical data obtained in a veterinary population can provide important data to support the development of novel diagnostics and therapeutics.

Available services

• Protocol design/review
• IACUC/regulatory support
• Budget building/review
• Grants management
• Clinical research coordinator/technical support
• REDCap
• Marketing/recruitment activities

Click here for full list of services and fees

Meet the Team (back to top)

Ian Davis, DVM, PhD - Director davis.2448@osu.edu

Current research in his laboratory is primarily focused on determining the impact of influenza A virus infection on alveolar type II (ATII) epithelial cell function at the single cell level in a mouse model of influenza-induced adult respiratory distress syndrome (ARDS). There are 3 major projects investigating: 1) effects of influenza on the ATII cell metabolome, with a particular focus on mitochondrial function and cellular energetics (funded by a new 4-year R01); 2) effects of influenza on the ATII cell miRnome, and the role of miR-155 in influenza pathogenesis (funded by an American Thoracic Society Foundation Recognition Award for Outstanding Established Investigators); and 3) differences between the transcriptomic profiles of virus-positive and virus-negative ATII cells from the same influenza-infected lung. The goal of these studies is to identify novel host determinants of influenza pathogenesis which can be targeted therapeutically. Finally,he is developing additional rodent and primary human ATII cell models that will allow us to test a newly-identified and recently patented therapeutic for ARDS.

Please remember to cite the Shared Resources!

Research reported in this publication was supported by The Ohio State University Comprehensive Cancer Center and the National Institutes of Health under grant number P30 CA016058.

We thank the XX Shared Resource at The Ohio State University Comprehensive Cancer Center, Columbus, OH for (XX)

(back to top)